To treat hyperlipidemia, oxidative stress or cancer. To treat viral infections, hypertension, cancer, inflammation, hyperlipidemia, diabetes and pain. Stonefish poisoning, topical infections, asthma *, malaria. Noni was used as an antipsychotic, anxiolytic, sedative, and hypnotic therapy and also to enhance food color stability. To treat bacterial and viral infections, cancer, pain, diabetes, nausea, gastric ulcers, liver disease, immune disorders, neuronal damage, cognition, helminthic infections, or to reduce oxidative stress, inflammation, inhibit oxidation of macromolecules (antioxidant capacity), improve memory impairment, cerebral blood flow, hyperglycemic and drug-induced hepatotoxicity.
Sores in mouth, peeling or cracking of toes, boils, pimples, blood impurities *, kava intoxication, insect infestations, tuberculosis, diabetes, blotchy skin *, heart trouble, stomach pain *, menstrual cramps *, heartburns, sore throat. To treat tuberculosis, helmintic infections, oxidative stress, open wounds, hyperlipidemia, and as an anti-allergen. Topical burns, headaches, fevers, neonatal inability to breath, bone fractures, menstrual cramps, gonorrhea *, back pain *, insect infestations, boils, rheumatic pain, ulcers, gout, internal bleeding, ringworm, neuralgia *. Natural products have emerged as one of the lucrative components of pharmaceutical industries generating more than $28 billion in revenues, globally. However, undesirable side effects of these anti-diabetic drugs, such as weight gain, hypoglycemia, and/or secondary failure possibly accelerated the resurgence of complementary and alternative medicine. Although lifestyle changes such as diet and exercise are cornerstones of T2D treatment, the majority of individuals require pharmacological intervention that may include metformin, sulfonylureas, thiazolidinediones or glucagon-like peptide-1 agonists. More often metabolic disorders including dyslipidemia, hypertension or vascular endothelial dysfunction also accompany T2D possibly leading to micro- and macro-vascular complications. In the United States, 25.8 million, or 8.3% of the population, including children and adolescents, suffer from T2D. Similarly, T2D-associated deaths are expected to double worldwide, from 2005 to 2030. Prevalence of T2D is expected to increase from 2.8% in 2000 to 4.4% by 2030.
Incidence of chronic inflammatory metabolic disorders such as type-2 diabetes (T2D) is escalating worldwide.
In this review we summarize the anti-diabetic potential of noni, differences between traditional and modern use of noni, along with beneficial clinical studies of noni products and challenges in clinical translation of noni’s health benefits. However, inadequate evidence regarding bioactive compounds, molecular targets, mechanism of action, pharmacokinetics, long-term safety, effective dosages, and/or unanticipated side effects are major roadblocks to successful translation “from bench side to bedside”. Noni products are perceived to be safe due to their “natural” origin. Unfortunately, noni’s exciting journey from Polynesian medicine to the research bench does not reach its final destination of successful clinical outcomes when translated into commercial products. Among noni’s several health benefits, others and we have demonstrated the anti-diabetic effects of fermented noni fruit juice in animal models. In 2003, the European Commission approved Tahitian noni juice as a novel food by the Health and Consumer Protection Directorate General. Commercial noni fruit juice has been marketed as a dietary supplement since 1996.
Morinda citrifolia (noni) has been used for centuries by Pacific Islanders to treat various ailments. Escalating trends of chronic diseases such as type-2 diabetes (T2D) have sparked a renewed interest in complementary and alternative medicine, including herbal products.